Guggenheim Initiates Coverage on Amylyx Pharmaceuticals (NASDAQ:AMLX)
Guggenheim began coverage on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) in a report issued on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $17.00 price target on the stock. Guggenheim’s price target indicates a potential upside of 171.57% from the stock’s previous close. AMLX has been the topic […]
Guggenheim began coverage on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) in a report issued on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $17.00 price target on the stock. Guggenheim’s price target indicates a potential upside of 171.57% from the stock’s previous close. AMLX has been the topic […]
